Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1930665 | 0.84 | TAAR1 (0.45) | TAAR1IDO1TSHRSLC6A2SLC6A4 | |
| SCHEMBL7666087 | 0.84 | TAAR1 (0.45) | GABRA1GABRB2TAAR1IDO1TSHR | |
| SCHEMBL6686376 | 0.82 | GABRA1 (0.54) | GABRA1GABRB2TAAR1IDO1ANPEP | |
| SCHEMBL625240 | 0.82 | TAAR1 (0.44) | GABRA1GABRB2TAAR1IDO1TSHR | |
| SCHEMBL29679614 | 0.82 | TAAR1 (0.44) | GABRA1GABRB2TAAR1IDO1TSHR | |
| SCHEMBL14997308 | 0.82 | TAAR1 (0.44) | GABRA1GABRB2TAAR1IDO1TSHR | |
| SCHEMBL6682510 | 0.82 | TAAR1 (0.44) | TAAR1IDO1TSHRSLC6A2SLC6A4 | |
| SCHEMBL15160736 | 0.82 | TAAR1 (0.44) | TAAR1IDO1TSHRSLC6A2SLC6A4 | |
| SCHEMBL5847127 | 0.82 | TAAR1 (0.50) | TAAR1IDO1SLC6A2SLC6A4 | |
| SCHEMBL5132667 | 0.82 | TAAR1 (0.44) | TAAR1IDO1TSHRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466746-A | Method for synthesizing arylamine compound by photochemical cobalt catalysis | 陕西师范大学 | 2024-01-30 | — | — | CN | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220388966-A1 | NOVEL COMPOUND HAVING ANTIBACTERIAL FUNCTION AGAINST SUPERBACTERIA AND SELECTIVE DETECTION FUNCTION OF HYPOCHLOROUS ACID, AND COMPOSITION AND SENSOR COMPRISING THE SAME | PUKYONG NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2022-12-08 | — | — | US | disclosed |
| WO-2022150167-A2 | NOVEL MACROCYCLIC OPIOID PEPTIDES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-109021022-B | Luminescent diazabenzimidazole carbene metal complexes | UDC 爱尔兰有限责任公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-01-21 | — | — | US | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0659182-A1 | PIPERAZINE DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| EP-0511879-B1 | Pyrazine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| WO-1995002593-A1 | PIPERAZINE DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-26 | — | — | WO | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
| EP-0421436-A2 | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
| US-4518799-A | GRIGNARD REAGENTS AND THEIR PREPARATION | THE UPJOHN COMPANY (US) | 1985-05-21 | — | — | US | disclosed |
| US-4443631-A | DIMETHYLFORMAMIDE OR DIMETHYLACETAMIDE SOLVENT 2-(2-FLUORO-4-BIPHENYLYL)PROPIONIC ACID INTERMEDIATE | THE UPJOHN COMPANY (US) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | GABRA1 1882/4885GABRB2 2786/4885TAAR1 4796/4885 |
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | CTNNBL1, CTNNB1, APC | GABRA1 4128/4885GABRB2 2946/4885TAAR1 4882/4885 |
| US-20220388966-A1 | NOVEL COMPOUND HAVING ANTIBACTERIAL FUNCTION AGAINST SUPERBACTERIA AND SELECTIVE DETECTION FUNCTION OF HYPOCHLOROUS ACID, AND COMPOSITION AND SENSOR COMPRISING THE SAME | HDHD5, MPO, HAO2 | GABRA1 2663/4885GABRB2 2320/4885TAAR1 1915/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | GABRA1 1995/4885GABRB2 1606/4885TAAR1 3993/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | GABRA1 4324/4885GABRB2 4213/4885TAAR1 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.